Related Experiment Video
Updated: Oct 1, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: sequence preference and the effect of C5 cytosine
Zhaohui Feng1, Wenwei Hu, William N Rom
1Department of Environmental Medicine, New York University Medical Center, Tuxedo, New York 10987, USA.
Abstract:
4-Aminobiphenyl (4-ABP) is a major etiological agent for human bladder cancer. Metabolically activated 4-ABP is able to interact with DNA to form adducts that may induce mutations and initiate carcinogenesis. Thirty to sixty percent of bladder cancer has a mutation in the tumor suppressor p53 gene, and the mutational spectrum bears unique features. To date the DNA binding spectrum of 4-ABP in the p53 gene is not known due to the lack of methodology to detect 4-ABP-DNA adducts at nucleotide sequence level. We have found that UvrABC nuclease, a nucleotide excision repair complex isolated from Escherichia coli, is able to incise specifically and quantitatively DNA fragments modified with N-hydroxy-4-aminobiphenyl (N-OH-4-ABP), an activated intermediate of 4-ABP. Using the UvrABC nuclease incision method, we mapped the binding spectrum of N-OH-4-ABP in DNA fragments containing exons 5, 7, and 8 of the human p53 gene and also determined the effect of C5 cytosine methylation on N-OH-4-ABP-DNA binding. We found that codon 285, a mutational hotspot at a non-CpG site in bladder cancer, is the preferential binding site for N-OH-4-ABP. We also found that C5 cytosine methylation greatly enhanced N-OH-4-ABP binding at CpG sites, and that two mutational hotspots at CpG sites, codons 175 and 248, became preferential binding sites for N-OH-4-ABP only after being methylated. These results suggest that both the unique DNA binding specificity of 4-ABP and cytosine methylation contribute to the mutational spectrum of the p53 gene in human bladder cancer.
Insights
4-Aminobiphenyl (4-ABP), a bladder cancer agent, binds to DNA, forming adducts. This study maps 4-ABP binding sites in the p53 gene, revealing methylation
Area of Science:
- Molecular biology
- Carcinogenesis research
- Genetics
Background:
- 4-Aminobiphenyl (4-ABP) is a known human bladder cancer agent.
- Metabolic activation of 4-ABP leads to DNA adducts, initiating carcinogenesis.
- The p53 tumor suppressor gene frequently harbors mutations in bladder cancer, with a unique mutational spectrum.
Purpose of the Study:
- To determine the DNA binding spectrum of 4-ABP in the human p53 gene.
- To investigate the influence of cytosine methylation on 4-ABP-DNA binding.
- To elucidate the contribution of 4-ABP binding and methylation to the p53 mutational spectrum in bladder cancer.
Main Methods:
- Utilized UvrABC nuclease from Escherichia coli for specific and quantitative incision of DNA fragments modified with N-hydroxy-4-aminobiphenyl (N-OH-4-ABP).
- Mapped N-OH-4-ABP binding sites within exons 5, 7, and 8 of the human p53 gene.
- Assessed the impact of C5 cytosine methylation on N-OH-4-ABP binding at specific DNA sites.
Main Results:
- Identified codon 285, a non-CpG hotspot in bladder cancer, as a preferential N-OH-4-ABP binding site.
- Demonstrated that C5 cytosine methylation significantly enhances N-OH-4-ABP binding at CpG sites.
- Showed that mutational hotspots at CpG sites (codons 175 and 248) become preferential binding sites for N-OH-4-ABP only after methylation.
Conclusions:
- The DNA binding specificity of 4-ABP contributes to the p53 mutational spectrum in bladder cancer.
- Cytosine methylation plays a crucial role in directing 4-ABP binding to specific hotspots within the p53 gene.
- Combined effects of 4-ABP binding and cytosine methylation explain unique p53 mutation patterns observed in human bladder cancer.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

